Skip to main content
. 2022 Feb 4;6(1):pkac007. doi: 10.1093/jncics/pkac007

Figure 1.

Figure 1.

The 18-month restricted mean survival time (RMST) analysis of progression-free survival (PFS) from the KEYNOTE-604 study. A) Reconstructed PFS curves comparing pembrolizumab or placebo, in addition to etoposide and platinum, for patients with extensive-stage small-cell lung cancer are shown. The numbers of patients at risk are shown below the graph. The 18-month restricted mean PFS times as the area under the PFS curve for B) placebo and C) pembrolizumab are shown.